Inventor · disambiguated record
Nicolai Wagtmann
Also filed as: WAGTMANN NICOLAI · WAGTMANN NICOLAÏ
16 granted patents·23 pending applications·82 citations·filing 1994–2025
92Inventor score
Top patents by PatentIndex Score
39 records- 0196US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0295US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0395US10329348B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2015·Granted Jun 25, 2019·16 cites·15 claims
- 0493US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 0592US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 0689US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 0787US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0887US11225519B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2019·Granted Jan 18, 2022·3 cites·18 claims
- 0987US11078274B2Siglec neutralizing antibodiesINNATE PHARMA·Filed 2017·Granted Aug 3, 2021·3 cites·23 claims
- 1084US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 1179US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1278US11623954B2Siglec-9-neutralizing antibodiesINNATE PHARMA·Filed 2018·Granted Apr 11, 2023·1 cites·12 claims
- 1376US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1476US2023235060A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1575US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1675US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1774US12037392B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·10 claims
- 1874US2023303691A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2023·Application pending·0 cites
- 1972US11083785B2Siglec-10 antibodiesINNATE PHARMA·Filed 2016·Granted Aug 10, 2021·1 cites·9 claims
- 2069US2023085847A1Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancerINNATE PHARMA·Filed 2022·Application pending·0 cites
- 2168US2021363249A1Siglec neutralizing antibodiesINNATE PHARMA·Filed 2021·Application pending·0 cites
- 2267US2020299383A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2364US2024124607A1Proteins binding nkg2d, cd16, and ceacam5MERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2464US2021122821A1Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Application pending·0 cites
- 2563US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2663US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2760US5808028AMolecular clone of a P58 receptor protein and uses thereofUS ARMY·Filed 1994·Granted Sep 15, 1998·17 cites·9 claims
- 2860US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2959US2022119533A1Heterodimeric fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3059US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3156US11447545B2Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancerINNATE PHARMA·Filed 2018·Granted Sep 20, 2022·0 cites·14 claims
- 3256US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3355US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3452US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3550US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3649US2023272041A1Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused ProteinsDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3744US2021221894A1Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tamsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3843US2020231679A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3937US2017306014A1Cross reactive siglec antibodiesINNATE PHARMA·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →